About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Novel Prognostic Markers in Renal Cancer | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT01002937

Novel Prognostic Markers in Renal Cancer

The purpose of this project is to analyze tumour tissue from a group of subjects with renal cell carcinoma, who have been treated at the Royal Marsden Hospital.

Lead sponsor: Royal Marsden NHS Foundation Trust•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Royal Marsden NHS Foundation Trust

Renal cancers have different clinical outcomes. The principal research objective is to study tumour tissue from renal cancer patients and try and understand why some cancers progress more rapidly than others. Further, another key aim of this study is to try and understand why some patients respond to treatment and others do not.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•The presence of histologically proven renal cell cancer
•The availability of paraffin embedded tissue
•Informed consent needed for tissue taken after January 2006 (date of enforcement of human tissue act)

Exclusion Criteria

•Absence of histological tissue
•Absence of consent to study tissue after January 2006

Related studies

RECRUITINGEARLY Phase 1

The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

NCT07645690 · Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

RECRUITINGPhase 3

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720 · Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), and more

RECRUITINGPhase 2

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

NCT06863311 · Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, and more

TDM for Optimized Outcome in Patients With mRCC.

NCT04659343 · Kidney Cancer, Renal Cell Carcinoma Metastatic, and more

RECRUITINGPhase 3

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 18, 2024Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment182

Start dateDec 2008

Last updatedJun 18, 2024

Condition

Renal Cell Carcinoma

Locations shown

The Royal Marsden NHS Foundation Trust

Sutton, Surrey

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 18, 2024Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions